Soleno Therapeutics, Inc. SLNO
At closeMay 15, 2026, 4:00 PM EDT
After hours · May 15, 4:00 PM ET
52-week range unavailable
- YTD
- +14.49%
- 1 year
- -29.33%
- Market cap
- 2.76B
- Profit margin
- 33.70%
- YTD return
- +14.49%
- 1-year return
- -29.33%
- Volume
- 4.97M
- Open
- 52.99
- Previous close
- 53.01
- Day's range
- 52.98 – 53.01
- Earnings date
- Aug 5, 2026
Key statistics
- Enterprise value
- 2.63B
- PEG ratio
- 0.02
- Price / sales
- 0.00
- Price / book
- 5.57
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 22.86%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
- Strong buy5
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 5, 2026
Expected Aug 5, 2026. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 5, 2026 | Jun 30, 2026 | 0.91 | — | — | — |
| May 7, 2026 | Mar 31, 2026 | 0.73 | 0.59 | -0.14 | -19.18% |
| Feb 25, 2026 | Dec 31, 2025 | 0.64 | 0.80 | +0.16 | +25.00% |
| Nov 4, 2025 | Sep 30, 2025 | 0.0575 | 0.47 | +0.41 | +717.39% |
| Aug 6, 2025 | Jun 30, 2025 | -0.53 | -0.09 | +0.44 | +83.02% |
| May 7, 2025 | Mar 31, 2025 | -1.14 | -0.95 | +0.19 | +16.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 17, 2026 | Wells Fargo | down | Overweight | Equal-Weight |
| Apr 8, 2026 | HC Wainwright & Co. | down | Buy | Neutral |
| Apr 7, 2026 | TD Cowen | down | Buy | Hold |
| Apr 7, 2026 | Wolfe Research | down | Outperform | Peer Perform |
| Apr 6, 2026 | Cantor Fitzgerald | down | Overweight | Neutral |
| Mar 18, 2026 | Oppenheimer | main | Outperform | Outperform |
About Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc. (SLNO) operates as a clinical-stage biopharmaceutical company, specializing in the creation and market introduction of groundbreaking treatments for uncommon illnesses. The cornerstone of its therapeutic pipeline is Diazoxide Choline Controlled-Release, a once-daily oral tablet aimed at addressing Prader-Willi Syndrome, currently progressing through an active Phase III clinical evaluation. Established in 1999, the Redwood City, California-headquartered firm adopted its current name, Soleno Therapeutics, Inc., in May 2017, having previously operated as Capnia, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 115
- Website
- soleno.life
News
Kuehn Law Encourages Investors of Soleno Therapeutics, Inc. to Contact Law Firm 
SLNO 8-DAY DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Securities Class Action Alleging Hyperphagia Drug Launch Disruptions - Hagens Berman 
SOLENO DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNO 
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – SLNO 
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO) 
SLNO DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Today's Lead Plaintiff Deadline in Securities Class Action 
Halper Sadeh LLC is Investigating Whether SLNO, APLS, HLX are Obtaining Fair Deals for their Shareholders 
Bronstein, Gewirtz & Grossman LLC Urges Soleno Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm 
DEADLINE ALERT for EOSE, SLNO, and NKTR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders 
Portnoy Law Firm Announces Class Action on Behalf of Soleno Therapeutics, Inc. Investors
Your note
Sign in to keep a note on SLNO — it syncs with the Stock Master app.